← SEC 公告列表 | OTLK SEC 公告 | Outlook Therapeutics, Inc.（OTLK）

重大事件 即時報告 8-K 2026-07-24

Outlook Therapeutics（納斯達克：OTLK）於2026年7月21日提交8-K表格，披露高層管理人員的新股權激勵及現金獎金安排，與公司核心產品ONS-5010（bevacizumab-vikg）生物製劑許可申請（BLA）進…

於 SEC 網站開啟原文

AI 繁中摘要

Outlook Therapeutics（納斯達克：OTLK）於2026年7月21日提交8-K表格，披露高層管理人員的新股權激勵及現金獎金安排，與公司核心產品ONS-5010（bevacizumab-vikg）生物製劑許可申請（BLA）進展掛鈎。 薪酬委員會批准向行政總裁Robert C. Jahr授予10萬份股票期權，以及向財務總監Lawrence A. Kenyon授予210,078份期權。期權行使價為每股1.4304美元，即授予日該股在納斯達克的收市價。期權將於2027年7月21日歸屬，前提是相關高管持續在職。這批期權旨在表彰兩人在2025及2026年推動ONS-5010 BLA的FDA審查及上訴過程中的貢獻。 此外，委員會亦批准兩筆現金花紅：Jahr可獲42萬美元，Kenyon可獲20萬美元。花紅的發放條件非常明確——必須在2026年7月31日或之前，FDA正式批准ONS-5010並就BLA作出有利裁決。委員會指出，此舉是為了肯定他們在BLA進展上的努力，同時補償2025年度未發放的年度花紅。花紅將在滿足條件後（扣除稅項及預扣）支付，並要求高管在支付日仍受僱於公司。 對投資者的潛在意義：這份8-K清楚顯示管理層對FDA短期內發出正面決定抱有極大期望，並以股權及現金獎勵直接綁定關鍵人物的留任與成果。若ONS-5010能在限期前獲批，將為公司帶來重大轉捩點；反之，花紅將無法觸發，但期權仍然有效。投資者應留意未來數日FDA的決定，這將直接影響股價及公司前景。
展開英文正文 
false
 0001649989
 
 
 
 
 
 
 
 0001649989
 
 
 2026-07-21
 2026-07-21
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section
13 OR 15(d) of The Securities Exchange Act of 1934 

 

Date
of Report (Date of earliest event reported): July
21, 2026

 

 

Outlook Therapeutics,
Inc.

(Exact
name of registrant as specified in its charter)

 

 
 Delaware
 001-37759
 38-3982704

 
 (State or other jurisdiction

of incorporation) 
 (Commission File Number) 
 (IRS Employer Identification No.) 

 
 

 
 
 111
 S. Wood Avenue, Unit
 #100

 Iselin, New Jersey

 08830

 
 (Address of principal executive offices) 
 (Zip Code) 

 
 

Registrant's telephone number, including area code:
(609) 619-3990

 

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 ¨ 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 
  
  

 
 ¨ 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 
  
  

 
 ¨ 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 
  
  

 
 ¨ 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 
 

Securities pursuant to Section 12(b) of the Act:

 

 
 Title of Each Class
  
 Trading Symbol(s)
  
 Name of Each Exchange
 on Which

 Registered

 
 Common Stock
  
 OTLK
  
 The Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨

 

 

  

  

 

 

 
 Item 5.02
 Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.

 
 

On July 21, 2026, the Compensation Committee (the
“Compensation Committee”) of the Board of Directors of Outlook Therapeutics, Inc. (the “Company”) approved the
grant of stock options to purchase shares of the Company’s common stock to the Company’s named executive officers as follows:
Robert C. Jahr, the Company’s Chief Executive Officer – 100,000 options and Lawrence A. Kenyon, the Company’s Chief
Financial Officer – 210,078 options (collectively, the “Option Awards”). The Option Awards were granted pursuant to
the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) and the Company’s standard form of stock option agreement
thereunder, with an exercise price of $1.4304 per share, the closing price of the Company’s common stock on The Nasdaq Capital Market
on the grant date. The Option Awards will vest and become exercisable on July 21, 2027, subject to the applicable officer’s continuing
service with the Company through such vesting date. The Option Awards were granted in recognition of Mr. Jahr’s and Mr. Kenyon’s
efforts and contributions during 2025 and 2026 in advancing the Company’s Biologics License Application (the “BLA”)
for ONS-5010 (bevacizumab-vikg) through the review and appeal processes with the U.S. Food and Drug Administration (the “FDA”).

 

In addition, on July 21, 2026, the Compensation
Committee approved the award of cash bonus opportunities to Mr. Jahr and Mr. Kenyon in the amounts of $420,000 and $200,000, respectively
(the “Bonus” and together, the “Bonuses”). Each Bonus will be earned and become payable only in the event that,
on or prior to July 31, 2026, the FDA approves ONS-5010 (bevacizumab-vikg) and renders a favorable decision with respect to the Company’s
BLA. The Compensation Committee awarded the Bonuses in recognition of Mr. Jahr and Mr. Kenyon’s contributions to the advancement
of the ONS-5010 (bevacizumab-vikg) BLA and the Company’s non-payment of annual bonuses for their 2025 service. Each Bonus, if earned,
will be paid, less applicable deductions and withholdings, subject to the applicable officer’s continuing service with the Company
through the date of payment.

 

The foregoing description of the Option Awards
does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2024 Plan and the form of stock
option agreement thereunder, each of which has been previously filed with the Securities and Exchange Commission.

 

  

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
 Outlook Therapeutics, Inc.

 
  
  

 
 Date: July 23, 2026
 By:
 /s/ Lawrence A. Kenyon

 
  
  
 Lawrence A. Kenyon

 
  
  
 Chief Financial Officer